tradingkey.logo

BRIEF-Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

ReutersFeb 18, 2025 12:11 PM

- Chimerix Inc CMRX.O:

  • CHIMERIX ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DORDAVIPRONE AS TREATMENT FOR RECURRENT H3 K27M-MUTANT DIFFUSE GLIOMA

  • CHIMERIX INC - FDA GRANTS PRIORITY REVIEW TO CHIMERIX'S DORDAVIPRONE, PDUFA DATE AUGUST 18, 2025

  • CHIMERIX INC - NO ADVISORY COMMITTEE MEETING PLANNED FOR CHIMERIX'S DORDAVIPRONE NDA

Source text: ID:nGNX2LbQJt

Further company coverage: CMRX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI